同种异体造血干细胞移植背景下霍奇金淋巴瘤PD-1阻断治疗的管理建议:驯服必要的恶
该共识工作组针对复发/难治性经典霍奇金淋巴瘤患者在自体移植后复发或不适合自体移植时使用PD-1阻断剂,以及后续接受同种异体造血干细胞移植(allo-HCT)前后PD-1阻断的使用问题,基于现有数据与经验提出共识建议,以指导临床决策直至获得更明确数据。
要点
- PD-1阻断是自体移植后复发或不适合自体移植的复发/难治性经典霍奇金淋巴瘤的有效治疗,但多数患者最终进展。
- allo-HCT仍是该背景下唯一显示治愈潜力的治疗,但初始报告提示移植相关早期毒性风险可能增加,可能与PD-1阻断的持续效应有关。
- allo-HCT后复发患者再次使用PD-1阻断似乎应答率高,但免疫毒性风险增加;工作组基于现有数据与经验提供共识建议。
核心结论
- 尽管缺乏前瞻性数据,关于allo-HCT前后使用PD-1阻断的可行性、结局、最佳时机和方法等问题在晚期cHL常规诊疗中不可避免,工作组基于现有数据与经验提供共识建议以帮助指导治疗决策,直至获得更明确数据。
研究设计与样本
- 该文件为工作组共识建议,基于现有数据与经验制定。
主要发现
- PD-1阻断在自体HCT后复发或不适合自体HCT的R/R cHL中为有效治疗,单药抗PD-1单克隆抗体与高应答率和持久缓解相关,但现有结果提示绝大多数患者最终会在治疗中进展。
- 初始报告提示在该背景下进行allo-HCT可能与早期移植相关毒性风险增加有关,可能由PD-1阻断的持续效应驱动。
- 接受allo-HCT的R/R cHL患者中多数会在移植后复发,治疗选择通常有限;此时PD-1阻断似乎产生高应答率,但伴随免疫毒性风险增加。
关键数值与推荐
- 工作组就allo-HCT前或后使用PD-1阻断提供共识建议,涉及可行性、结局、最佳时机和方法等方面;原文未报告具体推荐等级或数值标准。
临床怎么用
- 工作组基于现有数据与经验提供共识建议,以帮助指导晚期cHL患者在allo-HCT前后使用PD-1阻断的治疗决策,直至获得更明确数据。
局限性
- 原文指出缺乏前瞻性数据(scarcity of prospective data)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PD-1 blockade is an effective therapy in relapsed/refractory (R/R) classical Hodgkin Lymphoma (cHL) who have relapsed after or are ineligible for autologous hematopoietic cell transplantation (HCT). Although single-agent anti-PD-1 monoclonal antibodies (mAb's) are associated with high response rates and durable remissions, available results to date suggest that a large majority of patients will eventually progress on therapy. Many of these patients are potential candidates for allogeneic HCT (allo-HCT) after receiving anti-PD-1 mAb's, and allo-HCT remains for now the only treatment with demonstrated curative potential in this setting. However, initial reports suggested that allo-HCT in this setting may be associated with increased risk of early transplant-related toxicity, likely driven by lingering effects of PD-1 blockade. Furthermore, many patients with R/R cHL who undergo allo-HCT will relapse after transplantation, most often with limited treatment options. Here again, PD-1 blockade appears to yield high response rates, but with an increased risk of attendant immune toxicity. Many questions remain regarding the use of PD-1 blockade before or after allo-HCT, especially in relation to the feasibility, outcome, optimal timing, and method of allo-HCT after PD-1 blockade. Despite the scarcity of prospective data, these questions are unavoidable and must be tackled by clinicians in the routine care of patients with advanced cHL. We provide consensus recommendations of a working group based on available data and experience, in an effort to help guide treatment decisions until more definitive data are obtained.
引用
- Herbaux C, Merryman R, Devine S, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018. PMID: 29720488. doi:10.1182/blood-2018-02-811174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。